Third consensus on medical treatment of metastatic breast cancer.
about
Taxane-containing regimens for metastatic breast cancerArterial Therapies of Non-Colorectal Liver MetastasesMeta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancerLB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potentialRole of positron emission tomography for the monitoring of response to therapy in breast cancerIdentification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens.Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials.Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells.Survival differences among women with de novo stage IV and relapsed breast cancer.Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosisSingle-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial.Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker.Symptom management in metastatic breast cancer.Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical PracticeTreatment Considerations for the Management of Patients With Hormone Receptor-Positive Metastatic Breast Cancer.Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumabAdvances in the management of metastatic breast cancer: options beyond first-line chemotherapy.Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patientsRadiofrequency ablation of metastatic lesions from breast cancer.Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion.Optimal management of bone metastases in breast cancer patients.HER2 as a target for breast cancer therapy.Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.Bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer.Surgical management of noncolorectal cancer liver metastases.Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer.Palbociclib for the treatment of postmenopausal breast cancer - an update.Platinum-containing regimens for metastatic breast cancer.Etirinotecan pegol for the treatment of breast cancer.Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French Population-Based Study.The effect of delays in treatment for breast cancer metastasis on survival.Factors associated with mortality after breast cancer metastasis.In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium.Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status.
P2860
Q24187214-BC143F96-2763-4DDE-A8AD-C3A377C95D51Q26764990-D98730DB-58E9-431E-8F3F-FFF84AA8FB16Q26860469-8BBBCC04-13EE-4B2E-8B3C-37DE2D82EE12Q26865711-E84B8F59-E361-4D63-BC41-596C94C33A33Q28080621-534C5227-3CB0-46E6-BF76-8E7938CB3B58Q33718051-5093951E-2142-412E-B14B-D331F40868B0Q33729389-2867C4FF-C2D9-4376-B6B3-23B2F3899EAAQ33750192-8C206E2A-82B4-4206-9C1E-7E576A57C5F6Q34231099-4032A720-FC45-41AA-A0F9-5A9E1458D7E7Q34348721-FEB5BCBE-4817-4048-92C8-7EEB0D7D08A6Q34478105-0574A814-E3E1-489D-925D-4A039AF35888Q35227792-2D870D39-1BC3-4F81-8C40-1C8C291DF4A2Q35519793-E9365007-C9ED-40C5-BAAD-3A2A618F55F7Q35584763-56AF6D69-70FB-46D4-81CB-C32211E30FF5Q35599769-EE40B842-E53D-4DDF-B2EF-C051407C7CCAQ35667196-E4D2278B-C2AE-4932-B48D-76707F51E439Q35687540-1031401F-3B53-40FF-BC7E-F02536324A45Q35842769-862FC8A3-47C2-47F3-B26B-023692F82B64Q35872691-D6DC92BE-4690-44C5-9B3F-E271CCF971B2Q35926639-925B750A-65FD-4E3B-80CE-DCC3DD2701E6Q36069770-8B252B90-3E3C-40D8-A9E9-D901042E4115Q36571156-A2CBB91A-9FE9-4936-AA84-3F7BD7AB7F52Q36946596-2ED9D4D6-57DC-4386-AE8F-34C5C0E49A67Q37255122-6521A60C-23CA-435C-BC77-123A64565617Q37355487-F200E225-51B0-43AD-8FC6-96ABD75BDDADQ37705396-E5CE26B2-BA3B-4F37-84F0-004A66A97881Q37711732-7D428D80-A97C-4862-8C9C-8B6EB7AD6ED0Q37718401-22AC6C6D-5B1A-4173-AB89-6C49D55CA01BQ37950522-51E07077-879F-4DAB-BC44-CA8D5887FFD8Q38137763-373CF894-C2B4-427B-8B26-D68DB4BFE75CQ38224364-6B070412-5C1D-40F5-AD4D-73E891DB4FA5Q38527538-2C653CE2-74CE-449D-8056-4006DC662900Q38672387-6D8193BE-AC3B-4000-B51E-E1C665CB2EBCQ38712631-0518DFCB-7383-4A3A-A839-23D501AEDF76Q38735361-883617AF-0160-44F4-BD25-10A9B37BF5ACQ39115827-BB7CEA9D-5C87-4328-B5A7-CB31022E2971Q39990429-B40AA70B-B753-41CA-A9B6-2022E1B3D906Q40004897-80447E98-E297-40EF-9E09-5DB838B7115CQ41116986-FEFB1B44-EC0E-4C90-9D4E-EAA429E8461FQ41253382-FE5095CA-5066-461C-895F-0F6AC2B359E5
P2860
Third consensus on medical treatment of metastatic breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Third consensus on medical treatment of metastatic breast cancer.
@en
Third consensus on medical treatment of metastatic breast cancer.
@nl
type
label
Third consensus on medical treatment of metastatic breast cancer.
@en
Third consensus on medical treatment of metastatic breast cancer.
@nl
prefLabel
Third consensus on medical treatment of metastatic breast cancer.
@en
Third consensus on medical treatment of metastatic breast cancer.
@nl
P2093
P50
P356
P1433
P1476
Third consensus on medical treatment of metastatic breast cancer
@en
P2093
C C Zielinski
C Wiltschke
Central European Cooperative Oncology Group (CECOG)
E Stadtmauer
H J Burstein
H Zwierzina
J Bonneterre
K Possinger
P304
P356
10.1093/ANNONC/MDP261
P577
2009-07-16T00:00:00Z